Stockscreener 앱 받기
2.21
6.45%
0.134
Aspire Biopharma Holdings Inc 주식(ASBP)의 최신 뉴스
Aspire Biopharma Announces Reverse Stock Split - The Des Moines Register
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin - Ventura County Star
Aspire Biopharma Holdings sets share limit for stock incentive plan and approves equity award agreements - Investing.com Nigeria
Aspire Biopharma Adopts Equity Plan Limits and Award Agreements - TipRanks
Aspire Biopharma announces 1-for-40 reverse stock split By Investing.com - Investing.com Nigeria
Aspire Biopharma announces 1-for-40 reverse stock split - Investing.com
Tiny drug developer shrinks share count 40-to-1 to keep Nasdaq listing - Stock Titan
Aspire Biopharma names new executive chair - MSN
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA) - Panama City News Herald
Aspire Biopharma director Surendra Ajjarapu resigns from board By Investing.com - Investing.com Canada
Aspire Biopharma Announces Resignation of Board Director - TipRanks
Aspire Biopharma director Surendra Ajjarapu resigns from board - Investing.com
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member - Pocono Record
Aspire Biopharma Approves Key Proposals at Special Meeting - MSN
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - The Patriot Ledger
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
ASBP Stock Soars 32% After Favorable Feedback From FDA For Its Aspirin – Retail Expects Licensing Negotiations Soon - Stocktwits
FDA feedback clears path for Aspire Biopharma’s heart attack drug By Investing.com - Investing.com Nigeria
Aspire Biopharma Holdings, Inc.Common Stock (NQ: ASBP - FinancialContent
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Aspire Biopharma stock soars after FDA meeting clears path for heart attack drug - Investing.com Nigeria
Aspire Biopharma stock soars after FDA meeting clears path for heart attack drug By Investing.com - Investing.com South Africa
FDA feedback clears path for Aspire Biopharma’s heart attack drug - Investing.com India
FDA backs trial of faster-acting aspirin powder for heart attacks - Stock Titan
Aspire Biopharma Provides Q3 2025 Business Update - Oak Ridger
Aspire Biopharma (ASBP) Competitors and Alternatives 2026 - MarketBeat
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Aspire Biopharma Restructures Debt via Equity Exchange Agreements - TipRanks
Aspire Biopharma Holdings Signs Debt-for-Equity Exchange Agreements With Certain Debt Holders - TradingView — Track All Markets
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - Asbury Park Press
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Aspire Biopharma Holdings, Inc. Announces CEO Transition - aberdeennews.com
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - Pensacola News Journal
Aspire Biopharma Holdings, Inc. Warrant 2025-18.02.30 on Aspire Bio Hldgs Revenue Breakdown – NASDAQ:ASBPW - TradingView — Track All Markets
Aspire Biopharma Holdings, Inc. Warrant 2025-18.02.30 on Aspire Bio Hldgs - TradingView — Track All Markets
4.73%
0.92%
자본화:
|
볼륨(24시간):